Table 8.

Unadjusted and adjusted analysis using the Cox model for overall survival and recurrence-free survival (deaths from all causes), and for disease-specific survival and recurrence-free disease-specific survival (disease and treatment specific deaths only)

	Overall survival		Recurrence-free survival		Disease-specific survival		Recurrence-free disease-specific survival
	HR (95% CI)	p value	HR (95% CI)	p value	HR (95% CI)	p value	HR (95% CI)	p value
Unadjusted with full data (n=1408)	1·16 (0·87–1·54)	0·31	1·35 (1·06–1·73)	0·017	1·21 (0·86–1·70)	0·28	1·46 (1·11–1·23)	0·01
Adjusted* by covariates (n=1337 with imputation by mean for unknown baseline)†	1·04 (0·74–1·45)	0·83	1·25 (0·93–1·66)	0·14	1·12 (0·75–1·69)	0·57	1·33 (0·96–1·83)	0·083

HR=hazard ratio.

^*Adjusted for age (continuous), WHO performance status (0, 1, 2, 3, or 4), weeks between diagnosis and randomisation (≤6 weeks vs >6 weeks), surgical technique intended (open vs laparoscopic), type of incision (vertical vs Pfannenstiel vs other transverse), extent of tumour (confined vs spread), histology (endometrioid/adenocarcinoma vs other), depth of invasion (inner half vs endometrium, outer half vs endometrium), differentiation (grade 1, grade 2, grade 3), and centre (dummy variables and centres with less than five patients being grouped as one new centre).

^†71 patients were not included (37 standard surgery group, 34 lymphadenectomy group): 39 with no disease and 32 with differentiation not applicable (histology mixed epithelial stromal, sarcoma).